Literature DB >> 2249366

Pathogenesis of anti-Ro/SS-A autoantibody-associated cutaneous lupus erythematosus.

R D Sontheimer, D P McCauliffe.   

Abstract

Patients with several clinically distinctive types of cutaneous LE (e.g., SCLE, neonatal LE) frequently are found to have autoantibodies to the Ro RNP particle present in their circulation. Some studies suggest that these antibodies might be capable of directly triggering the type of histopathologic changes seen in SCLE and neonatal LE through immunologic effector mechanisms such as ADCC. Other investigative results, however, are not compatible with this hypothesis. A better understanding of the molecular configuration of the Ro small cellular RNP particle, the factors that regulate the expression of this complex autoantigen system in epidermal keratinocytes, and the overall pathogenetic potential of the Ro autoimmune response should provide some insight into this seeming paradox.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2249366

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  4 in total

1.  A case of neonatal lupus erythematosus showing transient anemia and hepatitis.

Authors:  Kyu Ri Kim; Tae Young Yoon
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

2.  [Drug-induced subacute cutaneous lupus erythematosus: repeated occurrence following treatment with terbinafine].

Authors:  G Wagner; M M Sachse
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

3.  Expression of intercellular adhesion molecule-1 (ICAM-1) and OKM5 in UVA- and UVB-induced lesions in patients with lupus erythematosus and polymorphous light eruption.

Authors:  E Stephansson; A M Ros
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

4.  Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts.

Authors:  S Garcia; J H Nascimento; E Bonfa; R Levy; S F Oliveira; A V Tavares; A C de Carvalho
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.